nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—Varicella—Azathioprine—Crohn's disease	0.0384	0.085	CcSEcCtD
Pimecrolimus—Condition aggravated—Mesalazine—Crohn's disease	0.0259	0.0573	CcSEcCtD
Pimecrolimus—Malignant melanoma—Azathioprine—Crohn's disease	0.0199	0.0441	CcSEcCtD
Pimecrolimus—Skin cancer—Azathioprine—Crohn's disease	0.0168	0.0371	CcSEcCtD
Pimecrolimus—Lymphoma—Azathioprine—Crohn's disease	0.0149	0.0329	CcSEcCtD
Pimecrolimus—Non-Hodgkin's lymphoma—Azathioprine—Crohn's disease	0.0149	0.0329	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Mercaptopurine—Crohn's disease	0.0147	0.0324	CcSEcCtD
Pimecrolimus—MTOR—epithelium—Crohn's disease	0.0133	0.0898	CbGeAlD
Pimecrolimus—MTOR—smooth muscle tissue—Crohn's disease	0.0129	0.0865	CbGeAlD
Pimecrolimus—MTOR—skin of body—Crohn's disease	0.0127	0.0854	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—Crohn's disease	0.012	0.0807	CbGeAlD
Pimecrolimus—MTOR—mammalian vulva—Crohn's disease	0.0116	0.0779	CbGeAlD
Pimecrolimus—FKBP1A—smooth muscle tissue—Crohn's disease	0.0116	0.0778	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—Crohn's disease	0.0114	0.0768	CbGeAlD
Pimecrolimus—Bacterial infection—Azathioprine—Crohn's disease	0.0113	0.0249	CcSEcCtD
Pimecrolimus—FKBP1A—mammalian vulva—Crohn's disease	0.0104	0.07	CbGeAlD
Pimecrolimus—MTOR—lymphoid tissue—Crohn's disease	0.0103	0.0691	CbGeAlD
Pimecrolimus—MTOR—digestive system—Crohn's disease	0.0102	0.0683	CbGeAlD
Pimecrolimus—FKBP1A—lymphoid tissue—Crohn's disease	0.00924	0.0622	CbGeAlD
Pimecrolimus—FKBP1A—digestive system—Crohn's disease	0.00913	0.0614	CbGeAlD
Pimecrolimus—Skin atrophy—Prednisone—Crohn's disease	0.0083	0.0184	CcSEcCtD
Pimecrolimus—Throat sore—Mesalazine—Crohn's disease	0.00657	0.0145	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Mesalazine—Crohn's disease	0.00651	0.0144	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Azathioprine—Crohn's disease	0.00609	0.0135	CcSEcCtD
Pimecrolimus—Leukoderma—Prednisone—Crohn's disease	0.00589	0.013	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Mesalazine—Crohn's disease	0.00584	0.0129	CcSEcCtD
Pimecrolimus—MTOR—lymph node—Crohn's disease	0.0058	0.039	CbGeAlD
Pimecrolimus—Breast disorder—Mercaptopurine—Crohn's disease	0.00572	0.0127	CcSEcCtD
Pimecrolimus—Acne—Mesalazine—Crohn's disease	0.00563	0.0124	CcSEcCtD
Pimecrolimus—Bone disorder—Mesalazine—Crohn's disease	0.00524	0.0116	CcSEcCtD
Pimecrolimus—Skin discolouration—Mesalazine—Crohn's disease	0.00524	0.0116	CcSEcCtD
Pimecrolimus—FKBP1A—lymph node—Crohn's disease	0.00521	0.0351	CbGeAlD
Pimecrolimus—Dysmenorrhoea—Mesalazine—Crohn's disease	0.00521	0.0115	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Mesalazine—Crohn's disease	0.00521	0.0115	CcSEcCtD
Pimecrolimus—Influenza like illness—Mesalazine—Crohn's disease	0.0046	0.0102	CcSEcCtD
Pimecrolimus—Skin exfoliation—Mesalazine—Crohn's disease	0.00452	0.01	CcSEcCtD
Pimecrolimus—Ear pain—Mesalazine—Crohn's disease	0.00403	0.00891	CcSEcCtD
Pimecrolimus—Immune system disorder—Mercaptopurine—Crohn's disease	0.00396	0.00875	CcSEcCtD
Pimecrolimus—Gastroenteritis—Mesalazine—Crohn's disease	0.00388	0.00858	CcSEcCtD
Pimecrolimus—Malnutrition—Mercaptopurine—Crohn's disease	0.00381	0.00844	CcSEcCtD
Pimecrolimus—Face oedema—Mesalazine—Crohn's disease	0.00332	0.00734	CcSEcCtD
Pimecrolimus—Arthralgia—Mercaptopurine—Crohn's disease	0.00325	0.00718	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00322	0.00713	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Mesalazine—Crohn's disease	0.00314	0.00694	CcSEcCtD
Pimecrolimus—Oedema—Mercaptopurine—Crohn's disease	0.00311	0.00689	CcSEcCtD
Pimecrolimus—Breast disorder—Mesalazine—Crohn's disease	0.00311	0.00687	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Mesalazine—Crohn's disease	0.00307	0.0068	CcSEcCtD
Pimecrolimus—Skin disorder—Mercaptopurine—Crohn's disease	0.00302	0.00669	CcSEcCtD
Pimecrolimus—CYP3A4—digestive system—Crohn's disease	0.00298	0.0201	CbGeAlD
Pimecrolimus—Acne—Prednisone—Crohn's disease	0.00298	0.00659	CcSEcCtD
Pimecrolimus—Influenza—Mesalazine—Crohn's disease	0.00297	0.00657	CcSEcCtD
Pimecrolimus—Asthma—Mesalazine—Crohn's disease	0.00297	0.00657	CcSEcCtD
Pimecrolimus—Pneumonia—Azathioprine—Crohn's disease	0.00292	0.00647	CcSEcCtD
Pimecrolimus—Infestation NOS—Azathioprine—Crohn's disease	0.00291	0.00643	CcSEcCtD
Pimecrolimus—Infestation—Azathioprine—Crohn's disease	0.00291	0.00643	CcSEcCtD
Pimecrolimus—Bronchitis—Mesalazine—Crohn's disease	0.00286	0.00632	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00284	0.00627	CcSEcCtD
Pimecrolimus—Viral infection—Prednisone—Crohn's disease	0.00277	0.00614	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00276	0.00611	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00271	0.006	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00269	0.00594	CcSEcCtD
Pimecrolimus—Pneumonia—Mesalazine—Crohn's disease	0.00266	0.00589	CcSEcCtD
Pimecrolimus—Infestation NOS—Mesalazine—Crohn's disease	0.00265	0.00586	CcSEcCtD
Pimecrolimus—Infestation—Mesalazine—Crohn's disease	0.00265	0.00586	CcSEcCtD
Pimecrolimus—Conjunctivitis—Mesalazine—Crohn's disease	0.00257	0.0057	CcSEcCtD
Pimecrolimus—Epistaxis—Mesalazine—Crohn's disease	0.0025	0.00553	CcSEcCtD
Pimecrolimus—Sinusitis—Mesalazine—Crohn's disease	0.00248	0.0055	CcSEcCtD
Pimecrolimus—Body temperature increased—Mercaptopurine—Crohn's disease	0.00246	0.00544	CcSEcCtD
Pimecrolimus—Skin exfoliation—Prednisone—Crohn's disease	0.00239	0.00529	CcSEcCtD
Pimecrolimus—Rhinitis—Mesalazine—Crohn's disease	0.00238	0.00527	CcSEcCtD
Pimecrolimus—Pharyngitis—Mesalazine—Crohn's disease	0.00236	0.00522	CcSEcCtD
Pimecrolimus—Immune system disorder—Azathioprine—Crohn's disease	0.00236	0.00522	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Azathioprine—Crohn's disease	0.00235	0.0052	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00229	0.00507	CcSEcCtD
Pimecrolimus—Eye disorder—Mesalazine—Crohn's disease	0.00222	0.00492	CcSEcCtD
Pimecrolimus—Immune system disorder—Mesalazine—Crohn's disease	0.00215	0.00475	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Mesalazine—Crohn's disease	0.00214	0.00474	CcSEcCtD
Pimecrolimus—Diarrhoea—Mercaptopurine—Crohn's disease	0.00213	0.00471	CcSEcCtD
Pimecrolimus—Erythema—Mesalazine—Crohn's disease	0.00207	0.00458	CcSEcCtD
Pimecrolimus—Back pain—Mesalazine—Crohn's disease	0.002	0.00443	CcSEcCtD
Pimecrolimus—Vomiting—Mercaptopurine—Crohn's disease	0.00198	0.00438	CcSEcCtD
Pimecrolimus—Rash—Mercaptopurine—Crohn's disease	0.00196	0.00434	CcSEcCtD
Pimecrolimus—Dermatitis—Mercaptopurine—Crohn's disease	0.00196	0.00434	CcSEcCtD
Pimecrolimus—Arthralgia—Azathioprine—Crohn's disease	0.00193	0.00428	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00192	0.00425	CcSEcCtD
Pimecrolimus—Angioedema—Mesalazine—Crohn's disease	0.00189	0.00418	CcSEcCtD
Pimecrolimus—Nausea—Mercaptopurine—Crohn's disease	0.00185	0.00409	CcSEcCtD
Pimecrolimus—Infection—Azathioprine—Crohn's disease	0.00184	0.00408	CcSEcCtD
Pimecrolimus—Cough—Mesalazine—Crohn's disease	0.00181	0.004	CcSEcCtD
Pimecrolimus—Skin disorder—Azathioprine—Crohn's disease	0.0018	0.00398	CcSEcCtD
Pimecrolimus—Arthralgia—Mesalazine—Crohn's disease	0.00176	0.0039	CcSEcCtD
Pimecrolimus—Face oedema—Prednisone—Crohn's disease	0.00176	0.00388	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00175	0.00387	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00169	0.00374	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Mesalazine—Crohn's disease	0.00169	0.00374	CcSEcCtD
Pimecrolimus—Oedema—Mesalazine—Crohn's disease	0.00169	0.00374	CcSEcCtD
Pimecrolimus—Infection—Mesalazine—Crohn's disease	0.00168	0.00371	CcSEcCtD
Pimecrolimus—Nervous system disorder—Mesalazine—Crohn's disease	0.00166	0.00366	CcSEcCtD
Pimecrolimus—Skin disorder—Mesalazine—Crohn's disease	0.00164	0.00363	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.0016	0.00354	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00154	0.0034	CcSEcCtD
Pimecrolimus—Paraesthesia—Mesalazine—Crohn's disease	0.00152	0.00336	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00152	0.00335	CcSEcCtD
Pimecrolimus—Dyspnoea—Mesalazine—Crohn's disease	0.00151	0.00333	CcSEcCtD
Pimecrolimus—Abdominal pain—Azathioprine—Crohn's disease	0.00147	0.00324	CcSEcCtD
Pimecrolimus—Body temperature increased—Azathioprine—Crohn's disease	0.00147	0.00324	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00146	0.00323	CcSEcCtD
Pimecrolimus—Pain—Mesalazine—Crohn's disease	0.00144	0.0032	CcSEcCtD
Pimecrolimus—Constipation—Mesalazine—Crohn's disease	0.00144	0.0032	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00138	0.00306	CcSEcCtD
Pimecrolimus—Hypersensitivity—Azathioprine—Crohn's disease	0.00137	0.00302	CcSEcCtD
Pimecrolimus—Urticaria—Mesalazine—Crohn's disease	0.00134	0.00297	CcSEcCtD
Pimecrolimus—Abdominal pain—Mesalazine—Crohn's disease	0.00134	0.00295	CcSEcCtD
Pimecrolimus—Body temperature increased—Mesalazine—Crohn's disease	0.00134	0.00295	CcSEcCtD
Pimecrolimus—Diarrhoea—Azathioprine—Crohn's disease	0.00127	0.00281	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mesalazine—Crohn's disease	0.00124	0.00275	CcSEcCtD
Pimecrolimus—Pruritus—Mesalazine—Crohn's disease	0.0012	0.00264	CcSEcCtD
Pimecrolimus—Vomiting—Azathioprine—Crohn's disease	0.00118	0.00261	CcSEcCtD
Pimecrolimus—MTOR—Insulin Signaling—SOCS1—Crohn's disease	0.00118	0.00294	CbGpPWpGaD
Pimecrolimus—Eye disorder—Prednisone—Crohn's disease	0.00118	0.0026	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TAB1—Crohn's disease	0.00117	0.00293	CbGpPWpGaD
Pimecrolimus—Rash—Azathioprine—Crohn's disease	0.00117	0.00259	CcSEcCtD
Pimecrolimus—Dermatitis—Azathioprine—Crohn's disease	0.00117	0.00258	CcSEcCtD
Pimecrolimus—Flushing—Prednisone—Crohn's disease	0.00117	0.00258	CcSEcCtD
Pimecrolimus—Headache—Azathioprine—Crohn's disease	0.00116	0.00257	CcSEcCtD
Pimecrolimus—MTOR—Leptin signaling pathway—JAK2—Crohn's disease	0.00116	0.0029	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Mesalazine—Crohn's disease	0.00116	0.00256	CcSEcCtD
Pimecrolimus—Immune system disorder—Prednisone—Crohn's disease	0.00114	0.00251	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—RASGRP1—Crohn's disease	0.00111	0.00277	CbGpPWpGaD
Pimecrolimus—MTOR—Interferon type I signaling pathways—STAT3—Crohn's disease	0.00111	0.00277	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—CD79A—Crohn's disease	0.0011	0.00277	CbGpPWpGaD
Pimecrolimus—Nausea—Azathioprine—Crohn's disease	0.0011	0.00244	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—TYK2—Crohn's disease	0.0011	0.00275	CbGpPWpGaD
Pimecrolimus—Erythema—Prednisone—Crohn's disease	0.0011	0.00242	CcSEcCtD
Pimecrolimus—Malnutrition—Prednisone—Crohn's disease	0.0011	0.00242	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—RBX1—Crohn's disease	0.00108	0.00271	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—HSPA1B—Crohn's disease	0.00108	0.00271	CbGpPWpGaD
Pimecrolimus—Vomiting—Mesalazine—Crohn's disease	0.00107	0.00238	CcSEcCtD
Pimecrolimus—MTOR—Immune System—ERAP2—Crohn's disease	0.00107	0.00269	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—TYK2—Crohn's disease	0.00107	0.00268	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RSPO3—Crohn's disease	0.00107	0.00267	CbGpPWpGaD
Pimecrolimus—Rash—Mesalazine—Crohn's disease	0.00107	0.00236	CcSEcCtD
Pimecrolimus—Dermatitis—Mesalazine—Crohn's disease	0.00106	0.00235	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—TYK2—Crohn's disease	0.00106	0.00265	CbGpPWpGaD
Pimecrolimus—Headache—Mesalazine—Crohn's disease	0.00106	0.00234	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—JAK2—Crohn's disease	0.00106	0.00265	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—JAK2—Crohn's disease	0.00105	0.00262	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—TYK2—Crohn's disease	0.00103	0.00258	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—TYK2—Crohn's disease	0.00103	0.00258	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—JAK2—Crohn's disease	0.00102	0.00255	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—STAT3—Crohn's disease	0.00102	0.00254	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—IL1B—Crohn's disease	0.00101	0.00254	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SEL1L—Crohn's disease	0.00101	0.00253	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—JAK2—Crohn's disease	0.00101	0.00253	CbGpPWpGaD
Pimecrolimus—Nausea—Mesalazine—Crohn's disease	0.001	0.00222	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—Crohn's disease	0.001	0.00251	CbGpPWpGaD
Pimecrolimus—Angioedema—Prednisone—Crohn's disease	0.001	0.00221	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—ACKR2—Crohn's disease	0.000986	0.00247	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—JAK2—Crohn's disease	0.000984	0.00246	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—JAK2—Crohn's disease	0.000984	0.00246	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CARD9—Crohn's disease	0.000968	0.00242	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—STAT3—Crohn's disease	0.000953	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—UBE2D1—Crohn's disease	0.000951	0.00238	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—Crohn's disease	0.000943	0.00236	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—STAT3—Crohn's disease	0.000942	0.00236	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MLN—Crohn's disease	0.000935	0.00234	CbGpPWpGaD
Pimecrolimus—Arthralgia—Prednisone—Crohn's disease	0.000932	0.00206	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000926	0.00205	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	0.000917	0.0023	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—TYK2—Crohn's disease	0.000914	0.00229	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—Crohn's disease	0.00091	0.00228	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—LTF—Crohn's disease	0.000908	0.00227	CbGpPWpGaD
Pimecrolimus—Oedema—Prednisone—Crohn's disease	0.000894	0.00198	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisone—Crohn's disease	0.000894	0.00198	CcSEcCtD
Pimecrolimus—Infection—Prednisone—Crohn's disease	0.000888	0.00196	CcSEcCtD
Pimecrolimus—Nervous system disorder—Prednisone—Crohn's disease	0.000876	0.00194	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—JAK2—Crohn's disease	0.000872	0.00218	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—Crohn's disease	0.000869	0.00218	CbGpPWpGaD
Pimecrolimus—Skin disorder—Prednisone—Crohn's disease	0.000868	0.00192	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—RIPK2—Crohn's disease	0.000865	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—IL6—Crohn's disease	0.000863	0.00216	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—TYK2—Crohn's disease	0.000862	0.00216	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MADCAM1—Crohn's disease	0.000858	0.00215	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—TYK2—Crohn's disease	0.000857	0.00214	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TAGAP—Crohn's disease	0.000855	0.00214	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—STAT3—Crohn's disease	0.00085	0.00213	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—JAK2—Crohn's disease	0.000823	0.00206	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—JAK2—Crohn's disease	0.000817	0.00205	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000814	0.0018	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—Crohn's disease	0.000808	0.00202	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Prednisone—Crohn's disease	0.000803	0.00178	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—STAT3—Crohn's disease	0.000776	0.00194	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—Crohn's disease	0.000776	0.00194	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICOSLG—Crohn's disease	0.000776	0.00194	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—Crohn's disease	0.000775	0.00194	CbGpPWpGaD
Pimecrolimus—Constipation—Prednisone—Crohn's disease	0.000764	0.00169	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—RSPO3—Crohn's disease	0.000748	0.00187	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—Crohn's disease	0.000735	0.00184	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—TYK2—Crohn's disease	0.000733	0.00183	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—GCKR—Crohn's disease	0.000732	0.00183	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Prednisone—Crohn's disease	0.000731	0.00162	CcSEcCtD
Pimecrolimus—Urticaria—Prednisone—Crohn's disease	0.00071	0.00157	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—SEL1L—Crohn's disease	0.000709	0.00177	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Prednisone—Crohn's disease	0.000707	0.00156	CcSEcCtD
Pimecrolimus—Abdominal pain—Prednisone—Crohn's disease	0.000707	0.00156	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—NOD1—Crohn's disease	0.000706	0.00177	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—TYK2—Crohn's disease	0.000701	0.00176	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—JAK2—Crohn's disease	0.000699	0.00175	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNGR2—Crohn's disease	0.000692	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—DEFA5—Crohn's disease	0.000692	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—TYK2—Crohn's disease	0.00069	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—JAK2—Crohn's disease	0.000687	0.00172	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—Crohn's disease	0.000672	0.00168	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—JAK2—Crohn's disease	0.000669	0.00167	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—TYK2—Crohn's disease	0.000659	0.00165	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Prednisone—Crohn's disease	0.000658	0.00146	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—JAK2—Crohn's disease	0.000658	0.00165	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—TYK2—Crohn's disease	0.000656	0.00164	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—TYK2—Crohn's disease	0.000652	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—STAT3—Crohn's disease	0.000649	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—TYK2—Crohn's disease	0.000649	0.00163	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR9—Crohn's disease	0.000648	0.00162	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SLC11A1—Crohn's disease	0.000647	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CCR6—Crohn's disease	0.000641	0.00161	CbGpPWpGaD
Pimecrolimus—Pruritus—Prednisone—Crohn's disease	0.000632	0.0014	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—JAK2—Crohn's disease	0.000629	0.00157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—JAK2—Crohn's disease	0.000626	0.00157	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—JAK2—Crohn's disease	0.000626	0.00157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—JAK2—Crohn's disease	0.000622	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—JAK2—Crohn's disease	0.000619	0.00155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	0.000619	0.00155	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Prednisone—Crohn's disease	0.000612	0.00135	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—TYK2—Crohn's disease	0.000611	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—TYK2—Crohn's disease	0.000611	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TYK2—Crohn's disease	0.000611	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—TYK2—Crohn's disease	0.000605	0.00152	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GPR65—Crohn's disease	0.000603	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RSPO3—Crohn's disease	0.0006	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—TYK2—Crohn's disease	0.0006	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—TYK2—Crohn's disease	0.000597	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—JAK2—Crohn's disease	0.000583	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—JAK2—Crohn's disease	0.000583	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JAK2—Crohn's disease	0.000583	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—JAK2—Crohn's disease	0.000578	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—JAK2—Crohn's disease	0.000572	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—JAK2—Crohn's disease	0.00057	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SEL1L—Crohn's disease	0.000569	0.00143	CbGpPWpGaD
Pimecrolimus—Vomiting—Prednisone—Crohn's disease	0.000568	0.00126	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CARD9—Crohn's disease	0.000564	0.00141	CbGpPWpGaD
Pimecrolimus—Rash—Prednisone—Crohn's disease	0.000564	0.00125	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisone—Crohn's disease	0.000563	0.00125	CcSEcCtD
Pimecrolimus—Headache—Prednisone—Crohn's disease	0.00056	0.00124	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—RBX1—Crohn's disease	0.000557	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ACKR2—Crohn's disease	0.000555	0.00139	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HSPA1B—Crohn's disease	0.000555	0.00139	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RBX1—Crohn's disease	0.000555	0.00139	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	0.000546	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—Crohn's disease	0.000541	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—Crohn's disease	0.000537	0.00135	CbGpPWpGaD
Pimecrolimus—Nausea—Prednisone—Crohn's disease	0.000531	0.00117	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—MLN—Crohn's disease	0.000526	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—Crohn's disease	0.000523	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—Crohn's disease	0.000518	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—JAK2—Crohn's disease	0.000516	0.00129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—STAT3—Crohn's disease	0.000513	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LTF—Crohn's disease	0.000511	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—UBE2D1—Crohn's disease	0.000509	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—STAT3—Crohn's disease	0.000504	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—Crohn's disease	0.000504	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—Crohn's disease	0.000504	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RIPK2—Crohn's disease	0.000493	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—UBE2D1—Crohn's disease	0.000488	0.00122	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—UBE2D1—Crohn's disease	0.000486	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TAGAP—Crohn's disease	0.000481	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RIPK2—Crohn's disease	0.000474	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ITGA4—Crohn's disease	0.000474	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RASGRP1—Crohn's disease	0.000465	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—STAT3—Crohn's disease	0.000461	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—Crohn's disease	0.000459	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TAB1—Crohn's disease	0.000455	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—Crohn's disease	0.000454	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NOD2—Crohn's disease	0.000447	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—Crohn's disease	0.000447	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RASGRP1—Crohn's disease	0.000447	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD79A—Crohn's disease	0.000445	0.00111	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR6—Crohn's disease	0.000429	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—STAT3—Crohn's disease	0.000428	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—Crohn's disease	0.000422	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SOCS1—Crohn's disease	0.000421	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RSPO3—Crohn's disease	0.00042	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—Crohn's disease	0.000419	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—STAT3—Crohn's disease	0.000418	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—TYK2—Crohn's disease	0.000416	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GCKR—Crohn's disease	0.000412	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NOD1—Crohn's disease	0.000411	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SOCS1—Crohn's disease	0.000405	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SEL1L—Crohn's disease	0.000399	0.000998	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—JAK2—Crohn's disease	0.000397	0.000994	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RBX1—Crohn's disease	0.000388	0.000972	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CXCL8—Crohn's disease	0.000386	0.000967	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—Crohn's disease	0.000379	0.000949	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTGER4—Crohn's disease	0.000378	0.000947	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CCR6—Crohn's disease	0.000373	0.000935	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR9—Crohn's disease	0.000365	0.000913	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC11A1—Crohn's disease	0.000364	0.000911	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—Crohn's disease	0.000358	0.000897	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SMAD3—Crohn's disease	0.000348	0.000871	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—Crohn's disease	0.000343	0.000859	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTPN2—Crohn's disease	0.000342	0.000855	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—UBE2D1—Crohn's disease	0.00034	0.000853	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GPR65—Crohn's disease	0.000339	0.000849	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RBX1—Crohn's disease	0.000338	0.000846	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—Crohn's disease	0.000337	0.000845	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RIPK2—Crohn's disease	0.00033	0.000827	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—Crohn's disease	0.000322	0.000807	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL3—Crohn's disease	0.000322	0.000806	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—Crohn's disease	0.000321	0.000803	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—Crohn's disease	0.000319	0.000799	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CRP—Crohn's disease	0.000318	0.000796	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—Crohn's disease	0.000318	0.000795	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RBX1—Crohn's disease	0.000312	0.000781	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HSPA1B—Crohn's disease	0.000312	0.000781	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RASGRP1—Crohn's disease	0.000311	0.00078	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—Crohn's disease	0.000311	0.000778	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR4—Crohn's disease	0.000305	0.000763	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—Crohn's disease	0.000299	0.000748	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	0.000299	0.000748	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—Crohn's disease	0.000299	0.000748	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—UBE2D1—Crohn's disease	0.000296	0.000742	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—Crohn's disease	0.000296	0.000741	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—Crohn's disease	0.000293	0.000735	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—Crohn's disease	0.000292	0.000732	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—Crohn's disease	0.000291	0.00073	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RIPK2—Crohn's disease	0.000287	0.000719	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ITGA4—Crohn's disease	0.000287	0.000719	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SOCS1—Crohn's disease	0.000282	0.000707	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ICAM1—Crohn's disease	0.00028	0.000702	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL3—Crohn's disease	0.00028	0.000701	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—UBE2D1—Crohn's disease	0.000273	0.000685	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RASGRP1—Crohn's disease	0.000271	0.000678	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD79A—Crohn's disease	0.00027	0.000676	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TAB1—Crohn's disease	0.000265	0.000664	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	0.000265	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NOD2—Crohn's disease	0.00026	0.000652	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SOCS1—Crohn's disease	0.000245	0.000615	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMAD3—Crohn's disease	0.000244	0.00061	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR6—Crohn's disease	0.000241	0.000605	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TYK2—Crohn's disease	0.000237	0.000594	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TYK2—Crohn's disease	0.000227	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—JAK2—Crohn's disease	0.000226	0.000567	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2RA—Crohn's disease	0.000226	0.000565	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL18—Crohn's disease	0.000221	0.000553	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RBX1—Crohn's disease	0.000218	0.000547	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—Crohn's disease	0.000217	0.000543	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—JAK2—Crohn's disease	0.000216	0.000542	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—Crohn's disease	0.000215	0.000538	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTGER4—Crohn's disease	0.000213	0.000532	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—Crohn's disease	0.000206	0.000516	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—Crohn's disease	0.000205	0.000514	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—Crohn's disease	0.000204	0.00051	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—Crohn's disease	0.000204	0.00051	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2RA—Crohn's disease	0.000196	0.000491	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SMAD3—Crohn's disease	0.000196	0.00049	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—UBE2D1—Crohn's disease	0.000191	0.00048	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RIPK2—Crohn's disease	0.000186	0.000465	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—Crohn's disease	0.000185	0.000463	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL3—Crohn's disease	0.000181	0.000453	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—Crohn's disease	0.000177	0.000444	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RASGRP1—Crohn's disease	0.000175	0.000439	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—Crohn's disease	0.00017	0.000426	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TYK2—Crohn's disease	0.000159	0.000398	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—Crohn's disease	0.000159	0.000398	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS1—Crohn's disease	0.000159	0.000397	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	0.000153	0.000382	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JAK2—Crohn's disease	0.000152	0.00038	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—Crohn's disease	0.000138	0.000346	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TYK2—Crohn's disease	0.000138	0.000346	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMAD3—Crohn's disease	0.000137	0.000343	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JAK2—Crohn's disease	0.000132	0.00033	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTMR3—Crohn's disease	0.00013	0.000325	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—Crohn's disease	0.000129	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TYK2—Crohn's disease	0.000128	0.00032	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2RA—Crohn's disease	0.000127	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—Crohn's disease	0.000125	0.000313	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—JAK2—Crohn's disease	0.000122	0.000305	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—Crohn's disease	0.000116	0.000291	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—Crohn's disease	0.000115	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—Crohn's disease	0.000115	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—Crohn's disease	0.000115	0.000287	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—Crohn's disease	0.000111	0.000279	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—Crohn's disease	0.000111	0.000278	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FADS1—Crohn's disease	0.000101	0.000253	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—Crohn's disease	9.68e-05	0.000242	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX4—Crohn's disease	9.46e-05	0.000237	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCKR—Crohn's disease	9.14e-05	0.000229	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TYK2—Crohn's disease	8.94e-05	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—Crohn's disease	8.94e-05	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAK2—Crohn's disease	8.53e-05	0.000214	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—Crohn's disease	7.78e-05	0.000195	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—Crohn's disease	7.77e-05	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—Crohn's disease	6.76e-05	0.000169	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—Crohn's disease	6.26e-05	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—Crohn's disease	6.24e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—Crohn's disease	4.37e-05	0.000109	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—Crohn's disease	2.91e-05	7.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—Crohn's disease	2.55e-05	6.37e-05	CbGpPWpGaD
